Symbols

ASND

Ascendis Pharma·NASDAQ

--(--)

ASND fundamentals

ASND Q4 2025 Earnings

Ascendis Pharma (ASND) released its earnings on Feb 11, 2026: revenue was 291.19M (YoY +61.74%), beat estimates; EPS was -0.65 (YoY +1.89%), missed estimates.

Revenue / YoY

291.19M

+61.74%

EPS / YoY

-0.65

+1.89%

Report date

Feb 11, 2026

ASND Earnings Call Summary for Q4,2025

Revenue Growth: YORVIPATH (EUR 477M/2025) and SKYTROFA (EUR 206M/2025) drove top-line performance, with 2026 targeting EUR 500M operating cash flow.
Pipeline Momentum: TransCon CNP FDA approval expected in late Feb 2026; Phase II combo trial for achondroplasia showed 3-4x linear growth improvement.
Strategic Expansion: 10 new YORVIPATH launches in 2026; 2030 goal of EUR 5B annual revenue via label expansion and new indications.
Competitive Edge: CEO dismissed competitors' approaches, highlighting Ascendis' hormone replacement therapy as superior to nonspecific kinase inhibitors.

Earnings

EPS

Revenue

Revenue & Expenses

ASND has released its 2025 Q4 earnings report, with revenue of 290.47M, reflecting a YoY change of 61.35%, and net profit of -39.39M, showing a YoY change of 1.08%. The Sankey diagram below clearly presents ASND's revenue sources and cost distribution.

Key Indicators

Ascendis Pharma (ASND) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Ascendis Pharma (ASND)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Ascendis Pharma (ASND)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Ascendis Pharma (ASND)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown